on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Progresses in Semaglutide Oral Dissolvable Film Development
BioNxt Solutions Inc. announced a step forward in its Semaglutide oral dissolvable film (ODF) program into active pharmaceutical development. This initiative is in collaboration with Gen-Plus GmbH, a German drug developer. The move highlights BioNxt’s strategic milestone as it enters the GLP-1 therapeutics market. This market is swiftly expanding globally, focusing on obesity, metabolic disorders, and type 2 diabetes.
Semaglutide, the main ingredient in many GLP-1 therapies, benefits from BioNxt's expertise in sublingual thin-film drug delivery systems. The new development aims to offer a needle-free, patient-friendly treatment option, enhancing convenience and adherence for patients managing chronic diseases.
The initial phase of development will span six to nine months. Key activities include formulation development, testing of components, and proof-of-concept evaluations. Outcomes from these studies could lead to the next steps in formulation optimization and scaling up the process.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news